🟢 Nasus Pharma is trading 11.51% up in after-hours trading after first NS003 Phase 1 patient dosed

Nasus Pharma is trading at $4.02, up 11.51% in after-hours trading following its September 29 announcement that the first patient was enrolled and dosed in NS003 Phase 1.

• NS003 is an intranasal ondansetron formulation for chemotherapy-related and post-operative nausea and vomiting.
• The study assesses pharmacokinetics and safety; topline data are expected in Q4 2026.
• The release confirms the milestone but reports no market reaction; after-hours pricing is from provided price context.